GPH.F - Galmed Pharmaceuticals Ltd.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 4.0000 |
| Open | 4.2600 |
| Bid | 4.1400 x 50000 |
| Ask | 4.5400 x 50000 |
| Day's Range | 4.1200 - 4.2600 |
| 52 Week Range | 0.3200 - 12.2250 |
| Volume | |
| Avg. Volume | 23 |
| Market Cap | 6.95M |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.6100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
PR NewswireGalmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023 and recent developments
- PR Newswire
Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced the initiation of a new clinical program to evaluate its lead compound, Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC).
- PR Newswire
Galmed Pharmaceuticals forms a Strategic Partnership with OnKai
Galmed Pharmaceuticals Ltd. (GLMD) reported today the execution of a definitive agreement for a $3M equity investment in OnKai Inc., leading an investment round of $6M. The agreement provides Galmed with a minority, but a strategic stake in Onkai. Concurrently, a strategic partnership agreement is being signed to advance both companies by leveraging their complementary knowledge and experience in their respective fields.
- PR Newswire
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (the "SEC").
- PR Newswire
Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the United States Patent and Trademark Office (USPTO) granted Galmed United States Patent 11,571,431 B2, which is expected to provide exclusivity of Aramchol meglumine salt until December 2034. With the latest patent, Galmed is fortifying the IP protection of its lead compound, Aramchol, extending Aramchol's IP prot
Simply Wall St.Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- PR Newswire
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases reported today full results from the Open-Label Part of the ARMOR study corroborating effects of Aramchol across all efficacy parameters.
- PR Newswire
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a biopharmaceutical company focused on the development of Aramchol and Amilo-5MER, announced today that on December 13, 2022, it received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is eligible for an additional 180 calendar day period, or until June 12, 2023, to regain compliance with the Nasdaq's minimum $1 bid price per share requirement.
ZacksGalmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade
Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- PR Newswire
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, fibrosis and other fibrotic indications, provides today a business update and reports financial results for the three and six months ended June 30, 2022.
ZacksEndo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada
Endo's (ENDP) subsidiary, Endo Ventures, signs agreement with Quoin Pharmaceuticals for developing/commercializing the latter's pipeline candidate, QRX003, for treating Netherton syndrome in Canada.
ZacksAldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
BenzingaGalmed's Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Model
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) announced results showing significant effects of Aramchol in a preclinical lung and gastrointestinal (GI) fibrosis model. Treatment with Aramchol resulted in statistically significant improvement in a validated bleomycin model of lung fibrosis (IPF), comparable to Pirfenidone, the gold standard treatment. Findings were seen across all important indicators for fibrosis severity, including hydroxyproline, a marker for collagen deposition in the fibrotic ti
- PR Newswire
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases, announced today results showing significant effects of Aramchol in pre-clinical model of both lung and gastrointestinal (GI) fibrosis.
- PR Newswire
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00
ZacksEvotec (EVO) Inks Drug Discovery Collaboration Deal With J&J
Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.